Smoldering multiple myeloma

S Vincent Rajkumar, Ola Landgren, María Victoria Mateos

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma (MM). There have been major advances in the diagnosis, prognosis, and management of SMM in the last few years. These include a revised disease definition, identification of several new prognostic factors, a classification based on underlying cytogenetic changes, and new treatment options. Importantly, a subset of patients previously considered SMM is now reclassified as MM on the basis of biomarkers identifying patients with an ≥80% risk of progression within 2 years. SMM has assumed greater significance on the basis of recent trials showing that early therapy can be potentially beneficial to patients. As a result, there is a need to accurately diagnose and risk-stratify patients with SMM, including routine incorporation of modern imaging and laboratory techniques. In this review, we outline current concepts in diagnosis and risk stratification of SMM, and provide specific recommendations on the management of SMM.

Original languageEnglish (US)
Pages (from-to)3069-3075
Number of pages7
JournalBlood
Volume125
Issue number20
DOIs
StatePublished - May 14 2015

Fingerprint

Multiple Myeloma
Biomarkers
Plasmas
Imaging techniques
Monoclonal Gammopathy of Undetermined Significance
Secondary Prevention
Plasma Cells
Cytogenetics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Rajkumar, S. V., Landgren, O., & Mateos, M. V. (2015). Smoldering multiple myeloma. Blood, 125(20), 3069-3075. https://doi.org/10.1182/blood-2014-09-568899

Smoldering multiple myeloma. / Rajkumar, S Vincent; Landgren, Ola; Mateos, María Victoria.

In: Blood, Vol. 125, No. 20, 14.05.2015, p. 3069-3075.

Research output: Contribution to journalArticle

Rajkumar, SV, Landgren, O & Mateos, MV 2015, 'Smoldering multiple myeloma', Blood, vol. 125, no. 20, pp. 3069-3075. https://doi.org/10.1182/blood-2014-09-568899
Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015 May 14;125(20):3069-3075. https://doi.org/10.1182/blood-2014-09-568899
Rajkumar, S Vincent ; Landgren, Ola ; Mateos, María Victoria. / Smoldering multiple myeloma. In: Blood. 2015 ; Vol. 125, No. 20. pp. 3069-3075.
@article{206fa19f8c594af9aea9b2d64e07bb15,
title = "Smoldering multiple myeloma",
abstract = "Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma (MM). There have been major advances in the diagnosis, prognosis, and management of SMM in the last few years. These include a revised disease definition, identification of several new prognostic factors, a classification based on underlying cytogenetic changes, and new treatment options. Importantly, a subset of patients previously considered SMM is now reclassified as MM on the basis of biomarkers identifying patients with an ≥80{\%} risk of progression within 2 years. SMM has assumed greater significance on the basis of recent trials showing that early therapy can be potentially beneficial to patients. As a result, there is a need to accurately diagnose and risk-stratify patients with SMM, including routine incorporation of modern imaging and laboratory techniques. In this review, we outline current concepts in diagnosis and risk stratification of SMM, and provide specific recommendations on the management of SMM.",
author = "Rajkumar, {S Vincent} and Ola Landgren and Mateos, {Mar{\'i}a Victoria}",
year = "2015",
month = "5",
day = "14",
doi = "10.1182/blood-2014-09-568899",
language = "English (US)",
volume = "125",
pages = "3069--3075",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "20",

}

TY - JOUR

T1 - Smoldering multiple myeloma

AU - Rajkumar, S Vincent

AU - Landgren, Ola

AU - Mateos, María Victoria

PY - 2015/5/14

Y1 - 2015/5/14

N2 - Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma (MM). There have been major advances in the diagnosis, prognosis, and management of SMM in the last few years. These include a revised disease definition, identification of several new prognostic factors, a classification based on underlying cytogenetic changes, and new treatment options. Importantly, a subset of patients previously considered SMM is now reclassified as MM on the basis of biomarkers identifying patients with an ≥80% risk of progression within 2 years. SMM has assumed greater significance on the basis of recent trials showing that early therapy can be potentially beneficial to patients. As a result, there is a need to accurately diagnose and risk-stratify patients with SMM, including routine incorporation of modern imaging and laboratory techniques. In this review, we outline current concepts in diagnosis and risk stratification of SMM, and provide specific recommendations on the management of SMM.

AB - Smoldering multiple myeloma (SMM) is an asymptomatic clonal plasma cell disorder. SMM is distinguished from monoclonal gammopathy of undetermined significance by a much higher risk of progression to multiple myeloma (MM). There have been major advances in the diagnosis, prognosis, and management of SMM in the last few years. These include a revised disease definition, identification of several new prognostic factors, a classification based on underlying cytogenetic changes, and new treatment options. Importantly, a subset of patients previously considered SMM is now reclassified as MM on the basis of biomarkers identifying patients with an ≥80% risk of progression within 2 years. SMM has assumed greater significance on the basis of recent trials showing that early therapy can be potentially beneficial to patients. As a result, there is a need to accurately diagnose and risk-stratify patients with SMM, including routine incorporation of modern imaging and laboratory techniques. In this review, we outline current concepts in diagnosis and risk stratification of SMM, and provide specific recommendations on the management of SMM.

UR - http://www.scopus.com/inward/record.url?scp=84929340214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929340214&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-09-568899

DO - 10.1182/blood-2014-09-568899

M3 - Article

VL - 125

SP - 3069

EP - 3075

JO - Blood

JF - Blood

SN - 0006-4971

IS - 20

ER -